GlobeNewswire Clinical StudiesOriginal article
Daré Bioscience Announces Peer-Reviewed Publication of Phase 1 Sildenafil Cream Study in Men Demonstrating Substantially Lower Systemic Exposure Versus Oral Sildenafil
Phase 1positiveSildenafil Cream, 3.6%Positive
AI Analysis
Summary
Daré Bioscience announced publication of Phase 1 data for its proprietary topical Sildenafil Cream in Sexual Medicine, showing substantially lower systemic exposure compared to oral sildenafil in men. The peer-reviewed publication strengthens the scientific foundation for the topical formulation.
Clinical Trial Data
Phase
Phase 1
Primary Endpoint
Met
Outcome Details
Peer-reviewed publication in Sexual Medicine demonstrating substantially lower systemic exposure compared to oral sildenafil
Importance:5/10
Sentiment:
0.60
Phase 1SildenafilTopical formulationPublicationSystemic exposure
Read the original article
Published by GlobeNewswire Clinical Studies on September 14, 2026 12:50 PM